Showing 15 posts of 292 posts found.

EMA validates HUTCHMED MAA for neuroendocrine tumour drug

July 16, 2021
Medical Communications EU, oncology

China-based biotech HUTCHMED has announced that the EMA has validated and accepted the Marketing Authorisation Application (MAA) for surufatinib, for …

Novel cancer therapy kick starts clinical trials

July 6, 2021
Manufacturing and Production oncology

The first patient has been dosed in Phase 1/2 trials investigating a new form of cancer therapy, gamma delta TCR …

Birmingham University & Nonacus to develop urine test for bladder cancer

July 1, 2021
bladder cancer, cfdna, oncology

The University of Birmingham has partnered with Nonacus to develop a non-invasive test for bladder cancer. The test, which is …


Personalised medicine in oncology: Where are we now?

June 30, 2021
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Cancer, oncology, presonalised medicine, surgery

The past decade has seen exponential growth in the field of oncology, with precision medicine at the forefront, driving positive …

Medical cannabis formulation kills breast cancer cells in trial

June 28, 2021
Sales and Marketing breast cancer, medical cannabis, oncology

UK-based pharma company, Apollon Formularies, have announced that their medical cannabis formulations were successful in killing triple-negative breast cancer (TNBC) …

New test proven to detect over 50 types of cancer

June 25, 2021
Medical Communications Cancer. test, US, oncology

Final results from a study into a new blood test that can detect more than 50 types of cancer have …

Breakthrough announced in circulating tumour cell research

June 18, 2021
Medical Communications Cancer, Circulating tumour cells, Precision Medicine, oncology

Liquid biopsy company, Angle, has announced results from their study in non-small cell lung cancer (NSCLC) which demonstrates the benefit …

New class of cancer-killing drugs identified

June 18, 2021
Medical Communications Cancer, oncology

Scientists have announced the identification of a new class of cancer drugs, known as POLQ inhibitors, that specifically kill cancer …


COVID chaos: Survey reveals global oncology trial disruptions

June 10, 2021
data, oncology

The pandemic has had a widespread impact across the healthcare industry and the world, however, a recent global survey from …

Astronomy & cancer: Researchers join forces to study CUP

June 7, 2021
Sales and Marketing oncology

Astronomers from Durham University have joined forces with cancer researchers to advance the diagnosis and treatment of cancer of unknown …

BMS announce new positive data from oesophageal cancer study

June 4, 2021
Medical Communications Cancer, oncology

Bristol Myers Squibb (BMS) has announced results from the Phase III CheckMate -648 trial in which nivolumab plus chemotherapy and …


AstraZeneca’s lung cancer drug gains EU approval

May 28, 2021
Medical Communications AstraZeneca, EU, lung cancer, oncology

AstraZeneca’s Tagrisso (osimertinib) has been approved in the EU for the adjuvant treatment of adult patients with early-stage (IB, II …


AstraZeneca secures MHRA licensing and NHS early access for lung cancer drug

May 7, 2021
Medical Communications Astrazenaca, oncology

AstraZeneca have announced that the MHRA has granted a license extension for Tagrisso (osimertinib) in the UK, for use as …

Data published on novel molecules for leukaemia treatment

April 27, 2021
Manufacturing and Production oncology

STORM Therapeutics have published new data in Nature on targeting RNA modifying enzymes for the development of new anti-cancer therapeutics, …


Enhertu now available via Cancer Drugs Fund following NICE decision

April 20, 2021
Manufacturing and Production AstraZeneca, breast cancer, oncology

AstraZeneca and Daiichi Sankyo have announced that NICE has approved Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund …

Latest content